- Home
- COE vs DRUG Comparison
COE vs DRUG Comparison
Compare COE & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COE
- DRUG
- Stock Information
- Founded
- COE 2011
- DRUG 2019
- Country
- COE Singapore
- DRUG United States
- Employees
- COE N/A
- DRUG N/A
- Industry
- COE Other Consumer Services
- DRUG Pharmaceuticals and Biotechnology
- Sector
- COE Real Estate
- DRUG Health Care
- Exchange
- COE Nasdaq
- DRUG Nasdaq
- Market Cap
- COE 177.0M
- DRUG 199.7M
- IPO Year
- COE 2016
- DRUG N/A
- Fundamental
- Price
- COE $30.40
- DRUG $33.63
- Analyst Decision
- COE
- DRUG Strong Buy
- Analyst Count
- COE 0
- DRUG 7
- Target Price
- COE N/A
- DRUG $83.25
- AVG Volume (30 Days)
- COE 11.3K
- DRUG 37.4K
- Earning Date
- COE 08-22-2025
- DRUG 08-13-2025
- Dividend Yield
- COE N/A
- DRUG N/A
- EPS Growth
- COE N/A
- DRUG N/A
- EPS
- COE N/A
- DRUG N/A
- Revenue
- COE $59,490,000.00
- DRUG N/A
- Revenue This Year
- COE N/A
- DRUG N/A
- Revenue Next Year
- COE N/A
- DRUG N/A
- P/E Ratio
- COE N/A
- DRUG N/A
- Revenue Growth
- COE 91.87
- DRUG N/A
- 52 Week Low
- COE $11.84
- DRUG $0.94
- 52 Week High
- COE $34.74
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- COE 59.96
- DRUG 64.40
- Support Level
- COE $28.50
- DRUG $31.80
- Resistance Level
- COE $29.38
- DRUG $36.50
- Average True Range (ATR)
- COE 1.01
- DRUG 2.44
- MACD
- COE -0.13
- DRUG 0.79
- Stochastic Oscillator
- COE 42.83
- DRUG 70.86
About COE 51Talk Online Education Group
51 Talk Online Education Group is an online education platform in China, with core expertise in English education. The company's mission is to make quality education accessible and affordable. It's online and mobile education platforms enable students across China to take live interactive English lessons with overseas foreign teachers, on demand. The Group operates in seven principal geographical area: China, Hong Kong, Philippines, Singapore, Malaysia, Thailand and Saudi Arabia.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.